| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jul 11, 2017CIDP and Autoimmune Epilepsy Researchers Granted 2017 Interlaken Leadership Awards
11 Jul 2017 SITGES, Spain — 11 July 2017 Global biotherapeutics leader CSL Behring today announced at the Peripheral Nerve Society’s annual meeting the winners of its annual Interlaken...
-
Jul 10, 2017Results of study, which compared AFSTYLA to octocog alfa, were presented at the International Society on Thrombosis and Haemostasis Congress 2017
10 Jul 2017 BERLIN — 10 July 2017 CSL Behring today presented data finding treatment with AFSTYLA® may result in low average product consumption without compromising efficacy in both the...
-
Jul 6, 2017New findings demonstrate CSL Behring’s promise to develop and deliver innovative treatments that improve patients’ lives
06 Jul 2017 MARBURG, Germany. — 06 July 2017 CSL Behring announced today that it will present new data from its recombinant coagulation factor development programs at the International Society...
-
Jun 23, 2017- HAEGARDA has been shown to reduce HAE attacks by 95 percent (median) in patients with a life-threatening, rare genetic disorder - Use of rescue medication was reduced by greater than 99 percent (1) - Subcutaneous administration builds and maintains steady-state C1-INH levels
23 Jun 2017 KING OF PRUSSIA, Pa. — 23 June 2017 Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved HAEGARDA® (C1 Esterase...
-
May 19, 2017Driven by its promise to save lives and protect people’s health, CSL Behring is honoured to be recognized by NORD, a tireless advocate for rare disease patients.
19 May 2017 KING OF PRUSSIA, Pa. — 19 May 2017 CSL Behring received the National Organization for Rare Disorders’ (NORD) 2017 Industry Innovation Award last night in Washington, D.C. for...
-
Apr 19, 2017- AFSTYLA is the first and only single-chain recombinant factor VIII product to treat haemophilia A.
19 Apr 2017 MELBOURNE, Australia — 19 April 2017 AFSTYLA is the first and only single-chain recombinant factor VIII specifically designed to treat haemophilia A AFSTYLA reduces the number of...
-
Apr 10, 2017CSL Behring marks World Hemophilia Day by donating its bleeding disorders medicines to the World Federation of Hemophilia (WFH).
10 Apr 2017 MONTREAL and KING OF PRUSSIA, Pa. — 10 April 2017 CSL Behring Marks World Hemophilia Day by Donating IUs of its Bleeding Disorders Medicines to the World Federation of Hemophilia...
-
Mar 31, 2017CSL Behring Sponsors the First Network of its Kind on the African Continent
31 Mar 2017 LIVINGSTONE, ZAMBIA — 31 March 2017 Global biotherapeutics leader CSL Behring today announced its commitment to sponsor the Jeffrey Modell North African Network, which will establish...
-
Mar 29, 2017CSL Behring’s Local Empowerment for Advocacy Development Grant helps rare disease patient groups and patients protect access to lifesaving therapies.
29 Mar 2017 KING OF PRUSSIA, Pa — 29 March 2017 Patients are the most compelling advocates for access to care, which is why CSL Behring awards Local Empowerment for Advocacy Development (LEAD)...
-
Mar 22, 2017The New England Journal of Medicine published data from the COMPACT study which demonstrated the safety and efficacy of CSL830 to prevent HAE attacks.
22 Mar 2017 KING OF PRUSSIA, Pa — 22 March 2017 Median reduction in hereditary angioedema (HAE) attack rate relative to placebo was 95% at the highest dose studied Data show up to 40% of HAE...